LSE - Delayed Quote USD
Novo Nordisk A/S (0TDD.L)
66.18
-3.24
(-4.67%)
At close: 7:14:26 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in DKK | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 8 | 24 | 23 |
| Avg. Estimate | 78.07B | 78.88B | 342.83B | 397.19B |
| Low Estimate | 76.12B | 75.52B | 325.71B | 353.69B |
| High Estimate | 80.63B | 81.46B | 361.02B | 423.44B |
| Year Ago Sales | 65.35B | 68.06B | 290.4B | 342.83B |
| Sales Growth (year/est) | 19.46% | 15.89% | 18.05% | 15.86% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0TDD.L | -- | -- | -- | -- |
| S&P 500 | 12.38% | 3.18% | 8.00% | 13.86% |
Upgrades & Downgrades
| Downgrade | BMO Capital: Outperform to Market Perform | 4/17/2025 |
| Upgrade | UBS: Sell to Buy | 1/8/2025 |
| Maintains | BMO Capital: Outperform to Outperform | 12/23/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 11/6/2024 |
| Maintains | Citigroup: Buy to Buy | 10/22/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 10/17/2024 |